Literature DB >> 2682691

Treatment of depressions resistant to tricyclic antidepressants, related drugs or MAO-inhibitors by lithium addition: review of the literature.

J Schöpf1.   

Abstract

Although it might be premature to consider the efficacy of lithium addition in patients unresponsive to conventional antidepressant drug treatment as established, the evidence is suggestive. Besides 26 open studies, four out of six controlled investigations reported a positive effect of combined therapy administered in the indicated sequence. Three controlled studies confirmed the original observation of de Montigny et al. that improvement may occur within 48 hours. Successful lithium addition was reported in different types of depression and after pretreatment with tricyclic antidepressants, related compounds or MAO-inhibitors. Preliminary recommendations with respect to the practical use of lithium addition are made.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2682691     DOI: 10.1055/s-2007-1014602

Source DB:  PubMed          Journal:  Pharmacopsychiatry        ISSN: 0176-3679            Impact factor:   5.788


  4 in total

Review 1.  Review of clinically important drug interactions with lithium.

Authors:  N S Harvey; S Merriman
Journal:  Drug Saf       Date:  1994-06       Impact factor: 5.606

Review 2.  Therapeutic options for treatment-resistant depression.

Authors:  Richard C Shelton; Olawale Osuntokun; Alexandra N Heinloth; Sara A Corya
Journal:  CNS Drugs       Date:  2010-02       Impact factor: 5.749

3.  Initial lithium augmentation improves the antidepressant effects of standard TCA treatment in non-resistant depressed patients.

Authors:  D Ebert; A Jaspert; H Murata; W P Kaschka
Journal:  Psychopharmacology (Berl)       Date:  1995-03       Impact factor: 4.530

Review 4.  Administration of antidepressants, diazepam and psychomotor stimulants further confirms the utility of Flinders Sensitive Line rats as an animal model of depression.

Authors:  D H Overstreet; O Pucilowski; A H Rezvani; D S Janowsky
Journal:  Psychopharmacology (Berl)       Date:  1995-09       Impact factor: 4.530

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.